221 related articles for article (PubMed ID: 26645980)
41. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
Chen PJ; Huang C; Meng XM; Li J
Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
[TBL] [Abstract][Full Text] [Related]
42. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
43. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy.
Patra S; Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Mishra SR; Behera BP; Jena M; Bhutia SK
Cell Mol Life Sci; 2019 Sep; 76(17):3263-3282. PubMed ID: 30982077
[TBL] [Abstract][Full Text] [Related]
44. Regulation of histone deacetylase activities.
Sengupta N; Seto E
J Cell Biochem; 2004 Sep; 93(1):57-67. PubMed ID: 15352162
[TBL] [Abstract][Full Text] [Related]
45. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.
Kim HS; Shen Q; Nam SW
J Korean Med Sci; 2015 Oct; 30(10):1375-80. PubMed ID: 26425032
[TBL] [Abstract][Full Text] [Related]
46. Role of Autophagy in Proteostasis: Friend and Foe in Cardiac Diseases.
Li J; Zhang D; Wiersma M; Brundel BJJM
Cells; 2018 Dec; 7(12):. PubMed ID: 30572675
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
48. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
Gomazkov OA
Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
[TBL] [Abstract][Full Text] [Related]
49. Genome-wide screening for target regions of histone deacetylases in cardiomyocytes.
Kaneda R; Ueno S; Yamashita Y; Choi YL; Koinuma K; Takada S; Wada T; Shimada K; Mano H
Circ Res; 2005 Aug; 97(3):210-8. PubMed ID: 16002748
[TBL] [Abstract][Full Text] [Related]
50. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
[TBL] [Abstract][Full Text] [Related]
51. Targeting the correct HDAC(s) to treat cognitive disorders.
Fischer A; Sananbenesi F; Mungenast A; Tsai LH
Trends Pharmacol Sci; 2010 Dec; 31(12):605-17. PubMed ID: 20980063
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylases: salesmen and customers in the post-translational modification market.
Brandl A; Heinzel T; Krämer OH
Biol Cell; 2009 Apr; 101(4):193-205. PubMed ID: 19207105
[TBL] [Abstract][Full Text] [Related]
53. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming.
Borutinskaitė V; Navakauskienė R
Int J Mol Sci; 2015 Aug; 16(8):18252-69. PubMed ID: 26287160
[TBL] [Abstract][Full Text] [Related]
54. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
Saha RN; Pahan K
Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
[TBL] [Abstract][Full Text] [Related]
55. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
56. Role of Histone Deacetylases in Monocyte Function in Health and Chronic Inflammatory Diseases.
Tordera RM; Cortés-Erice M
Rev Physiol Biochem Pharmacol; 2021; 180():1-47. PubMed ID: 33974124
[TBL] [Abstract][Full Text] [Related]
57. Linking epigenetics to lipid metabolism: focus on histone deacetylases.
Ferrari A; Fiorino E; Giudici M; Gilardi F; Galmozzi A; Mitro N; Cermenati G; Godio C; Caruso D; De Fabiani E; Crestani M
Mol Membr Biol; 2012 Nov; 29(7):257-66. PubMed ID: 23095054
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic treatment of neurological disease.
Gray SG
Epigenomics; 2011 Aug; 3(4):431-50. PubMed ID: 22126204
[TBL] [Abstract][Full Text] [Related]
59. Mass spectrometry in epigenetic research.
Beck HC
Methods Mol Biol; 2010; 593():263-82. PubMed ID: 19957154
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
